CAPROLACTAM CHEMICALS LTD.

Caprolactam Chemicals Ltd has announced the closure of its trading window for designated persons. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of financial results for the quarter ended June 30, 2026. The company has informed its designated persons not to trade in its securities during this period, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The date for the board meeting to declare these financial results will be communicated separately.

Caprolactam Chemicals Ltd's board approved the audited financial results for the quarter and financial year ended March 31, 2026. The company's revenue from operations for FY26 stood at ₹1,055.75 lakhs, compared to ₹673.96 lakhs in FY25. Net profit after tax for FY26 was ₹176.12 lakhs, a significant improvement from a loss of ₹(70.87) lakhs in the previous year. M/s. Shrey Pandey & Associates were appointed as the Internal Auditor for FY 2026-27.

Caprolactam Chemicals Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The trading window has been closed from April 1, 2026, and will remain closed until 48 hours after the public announcement of the results. The information is available on the company's website.

Caprolactam Chemicals Ltd is not required to comply with Regulation 23(9) of the SEBI (LODR) Regulations, 2015, concerning Related Party Transaction disclosures. As of March 31, 2025, the company's paid-up equity share capital is ₹4,60,00,000 and its net worth is ₹4,95,89,569, falling below the threshold of ₹10 crore paid-up equity share capital and ₹25 crore net worth as specified in Regulation 15(2) of SEBI (LODR) Regulations, 2015.

Caprolactam Chemicals Ltd has announced the closure of the trading window for dealing in securities of the company by designated persons. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and BSE Circular No. List/Comp/01/2019-20 Dated April 2, 2019. The trading window will remain closed from 1st April, 2026 till 48 hours of the declaration of financial results for the quarter ended March 31, 2026. The date of the board meeting for the declaration of financial results has not been announced yet.

Caprolactam Chemicals Ltd has announced its unaudited standalone financial results for the quarter ended December 31, 2025. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 13, 2026. The company reported a (loss) before tax of INR 152.57 Crore. The Board also approved the revision in remuneration of the Chief Financial Officer cum Whole-Time Director and the Managing Director. Additionally, the Board approved related party transactions with Ms. Shital Bhanushali and a revision in consultancy fees payable by the company to a related party, Mr. Shankar Bhanushali.

Caprolactam Chemicals Ltd. has announced a Board of Directors meeting on February 13, 2026, to consider and approve the unaudited financial results for the quarter ended December 31, 2025. The company will also consider recommending a dividend payment on equity shares. The trading window for all designated persons and their relatives has been closed from January 1, 2026, and will remain closed for 48 hours after the declaration of the financial results.

Caprolactam Chemicals Ltd has announced the closure of the trading window for designated persons, in accordance with SEBI regulations and BSE circular. The closure will be effective from January 1, 2026, until 48 hours after the declaration of financial results for the quarter ended December 31, 2025. The date of the board meeting for the financial results declaration will be informed in due course.

Caprolactam Chemicals Ltd has submitted a Form C disclosure received from Mrs. Shital S. Bhanushali, a Promoter of the Company, in respect of Purchase of equity shares carried out on 28/11/2025. The disclosure was received by the Company on 29/11/2025 and filed with the exchange within the prescribed timelines. Mrs. Bhanushali purchased 3,60022 equity shares, raising her holding to 7.83%.

Caprolactam Chemicals Ltd has submitted a Form C disclosure received from Mrs. Shital S. Bhanushali, a Promoter of the company. The disclosure pertains to the purchase of equity shares carried out on 28/11/2025. The company received the disclosure on 29/11/2025 and is filing it with the exchange within the prescribed timelines.